GlaxoSmithKline's quadrivalent influenza vaccine has been granted marketing authorisation in Germany and the UK. The four-strain vaccine is the first to be approved in a European country for active immunisation of adults and children from three years of age for the prevention of influenza disease caused by the two influenza A and two influenza B virus subtypes contained within the vaccine.
The vaccine will be marketed as Influsplit Tetra in Germany, and Fluarix Tetra in the UK. The approval follows the FDA's green light given to the GSK four-strain vaccine in December 2012 (see the Top 4 influenza vaccine FDA approvals). The addition of a second B strain should allow the vaccine to provide a broader influenza strain coverage compared to current trivalent vaccines available in Europe. GSK say that vaccine â€˜mismatch' has been a problem in previous seasons, where the predominant circulating B strain has been different to the one B strain included in the trivalent vaccine.
GSK say that the vaccine is expected to be available for use in Germany and the UK for the 2013/2014 â€˜flu season. We can also expect to see regulatory decisions made for the GSK vaccine in Australia, Switzerland and Taiwan over the coming months.
Do you think that quadrivalent vaccines are going to overtake trivalent vaccines in Europe?
Why not join our discussion on our LinkedIn discussion page.
If you'd like to hear more about strategy and innovation in vaccines, including several talks on the influenza vaccine landscape and influenza vaccine development, you might be interested in attending the World Vaccine Congress & Expo 2013, 16-18 April 2013, at the Gaylord National Hotel and Convention Center, Washington DC.
See the press release from GSK.